The Drug Enforcement Administration announced on August 29, 2024 that it will hold a public hearing to address the proposed rescheduling of marijuana from Schedule I to Schedule III of the federal Controlled Substances Act (CSA). Β The hearing will take place on December 2, 2024 at 9 am ET at
Articles Discussing Drugs & Alcohol In The Workplace.
Department of Justice Publishes Notice of Proposed Rulemaking to Reschedule Marijuana to Schedule III
The Department of Justice (DOJ) published aΒ Notice of Proposed RulemakingΒ to reschedule marijuana from Schedule I to Schedule III of the federal Controlled Substances Act (CSA) in the Federal Register on May 21, 2024. If the rule is finalized, marijuana would be considered a drug with βmoderate to low potential for physical and psychological dependenceβ and would be available for medical useΒ only, notΒ legalized at the federal level.
A Continuing Discussion on the Opioid Epidemic and the Workplace β Part 4
Executive Summary:Β This is Part 4 of a series of Alerts exploring different facets of the ongoing opioid addiction crisis afflicting our country. Our initialΒ AlertΒ on June 12, 2023 outlined the big-picture issues associated with this epidemic. Our September 7, 2023Β AlertΒ (Part 1) addressed how to identify a potential addiction issue, when to engage, and how to engage on the same.
Live from Workplace Horizons 2024 β Episode 1: What Employers Need to Know About Keeping Their Workplace Safe, Drug-Free and Productive
Welcome and thank you for joining us for this special edition of We get workβ’, live from Jackson Lewisβ Workplace Horizons 2024 from the Lotte New York Palace in New York City and the Wynn in Las Vegas. What follows are high level conversations on conference programs and why they were important topics to present now.
DOJ Plans to Reclassify Marijuana From Schedule I to Lower-Risk Schedule III Drug
On April 30, 2024, following a months-long process, the U.S. Department of Justice (DOJ) circulated a proposal to reclassify marijuana from a Schedule I to a Schedule III controlled substance. This historic moveβlikely the most substantial change to federal drug policy in more than fifty yearsβwould place marijuana amongst the
U.S. Drug Enforcement Administration Recommends Rescheduling Marijuana To Schedule III, Similar to Tylenol With Codeine
The U.S. Drug Enforcement Administration will recommend that marijuana should be rescheduled from a Schedule I drug to a Schedule III drug, according to an announcement made April 30, 2024 by the U.S. Department of Justice.Β This means that marijuana would be considered a drug with βmoderate to low potential
Off-Duty Conduct Protections for Employeesβ 4/20 Celebrations: A Look at the High Points of a Few Statesβ Marijuana Laws
With the arrival of the unofficial annual holiday known as β4/20,β employers can celebrate by reminding themselves of the state laws that could protect employeesβ off-duty 4/20 celebrations.
A Continuing Discussion on the Opioid Epidemic in the Workplace β Part 3
Executive Summary:Β This is Part 3 of a series of Alerts exploring different facets of the ongoing opioid addiction crisis afflicting our country. Our initialΒ AlertΒ on June 12, 2023 outlined the big-picture issues associated with this epidemic. Our September 7, 2023Β AlertΒ (Part 1) addressed how to identify a potential addiction issue, when to engage, and how to engage on same. Our December 11, 2023Β AlertΒ (Part 2) focused on some of the medical issues related to addiction and why it is helpful for employers to better understand these issues when navigating an addiction scenario with an employee. This Alert (Part 3) focuses on navigating the rehabilitation process.
Dear Littler: What are the substance use concerns of workplaces past, present, and future?
Dear Littler,
Iβm in charge of organizing our holiday party this year. To keep things civil, weβre limiting alcohol and reminding employees that although our state has legalized the recreational use of marijuana, there is to be no pot at the potluck. I figured now was a good
Continuing Discussion on the Opioid Epidemic in the Workplace β Part 2
Executive Summary:Β This is the second of multiple Alerts exploring different facets of the ongoing opioid addiction crisis afflicting our country.Β Our June 12, 2023Β AlertΒ outlined the big-picture issues associated with this epidemic.Β Our September 7, 2023Β AlertΒ (Part 1) addressed how to identify a potential addiction issue and when and how to engage on the issue. This Alert focuses on some of the medical concerns related to addiction and why it is helpful for employers to better understand these concerns when navigating an addiction scenario with an employee.
Caroline Berdzik Shares with Business Insurance the Issues Confronting Employers Regarding Making Naloxone Available in the Workplace
This year has seen the federal approval of over-the-counter availability of naloxone β commonly known as brands Narcan and Evzio β which is used to counteract opioid overdoses and considered a lifesaving medication. As such, there is a push for employers to supply naloxone as part of workplace first-aid kits.
Stocking Naloxone in the Workplace: What Employers Need to Consider
It is well known that opioid overdoses have occurred at epidemic levels in the United States for years. According to the U.S. Centers for Disease Control and Prevention (CDC), opioid overdose deaths have increased from 21,089 in 2010, to 47,600 in 2017, to more than 80,000 in 2021 and 2022.
How Much Is Too Much? Drinking, Drugs, and Trucking
βBut I only had two beers.β
HHS Recommends that Marijuana be Reclassified as Schedule III Controlled Substance
A Continuing Discussion on the Opioid Epidemic and the Workplace β Part 1
Executive Summary:Β As promised, this is the first of multiple Alerts that will explore the details of the ongoing opioid epidemic, identify relevant issues for employers to analyze, and provide suggestions on how to effectively navigate this complicated and highly problematic issue.